## (19) World Intellectual Property Organization

International Bureau



# 

(43) International Publication Date 8 July 2004 (08.07.2004)

(10) International Publication Number WO 2004/056874 A3

(51) International Patent Classification7: 16/28, A61K 39/395, A61P 35/00

C07K 16/30,

Kristian, Hobold [DK/DE]; Daiserstrasse 50, 81371 München (DE).

(21) International Application Number:

PCT/EP2003/014756

(74) Agents: FLEUCHAUS, Andrea et al.; Melchiorstr.42. 81479 München (DE).

(22) International Filing Date:

. 22 December 2003 (22.12.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/435,893 03000615.9 20 December 2002 (20.12.2002) 15 January 2003 (15.01.2003)

(71) Applicant (for all designated States except US): XERION PHARMACEUTICALS AG [DE/DE]; Sauerbruchstr. 50, 81377 München (DE).

(71) Applicant (for US only): TUFTS UNIVERSITY [US/US]; 136 Harrison Avenue, Boston, MA 02111 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): UNGER, Christine, Margarete [DE/DE]; Arndt Strasse 11, 80469 München (DE). BESTE, Gerald [DE/DE]; Helmpertstr. 2, 80687 München (DE). ZEHETMEIER, Carolin [DE/DE]; St. Martin Strasse 3, 81541 München (DE). LAIN, Blanca [ES/US]; 100 Washington St. Apt. 7, Brighton, MA 02135 (US). TORELLA, Claudia [IT/DE]; Brodstr. 6A, 81829 München (DE). NIEWÖHNER, Jens [DE/DE]; Wengleinstrasse 3, 81477 München (DE). JAY, Daniel, G. [US/US]; 45 Bigelow Street, Brighton, MA 02135 (US). EUSTACE, Brenda, K. [US/US]; 95 Coolidge Street #2. Brookline, MA 02446 (US). KNAUER, Roland [DE/DE]; Gabelsberger Strasse 63, 80333 München (DE). JENSEN,

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### Declaration under Rule 4.17:

of inventorship (Rule 4.17(iv)) for US only


- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report: 9 December 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NEUROPILIN-1 INHIBITORS

(57) Abstract: The present invention relates to molecules interfering with the function of neuropilin-1 in the context of angiogenesis and the treatment of cancer. Molecules, polypeptides, antibodies, compositions and methods are provided that are useful for reducing, inhibiting or treating angiogenesis, the invasion of blood vessels into tumors, and/or the invasion or the metastatic potential of specific tumor cells. Additionally, a method is provided that allows identifying molecules, which interfere with the functionality of neuropilin-1. Furthermore, a method is provided that allows determining whether a naturally occurring tumor cell depends on functional neuropilin-1 for its invasiveness and/or metastatic potential.





International Application No

EP 03/14756

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 CO7K16/30 CO7K16/28

A61K39/395

A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

#### B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, Sequence Search, MEDLINE, BIOSIS, EMBASE, WPI Data, PAJ, CHEM ABS Data

Category °	Citation of document, with indication, where appropriate, of the r	elevant passages	Relevant to claim No.
X	WO 99/55855 A (LEE YOON S ;WRIGH (CA); YOUNG AIPING H (CA); GENES 4 November 1999 (1999-11-04) examples page 2, lines 10-12 page 6, lines 13-22	1-22	
		<b>-/</b>	
	• • • • • • • • • • • • • • • • • • •		
V. Forth	Or decumpate on listed in the continue to		
	er documents are listed in the continuation of box C.	Patent family members are liste	d in annex.
<ul> <li>Special categories of cited documents:</li> <li>A' document defining the general state of the art which is not considered to be of particular relevance</li> <li>E' earlier document but published on or after the international filing date</li> <li>L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</li> <li>C' document reterring to an oral disclosure, use, exhibition or other means</li> <li>P' document published prior to the international filing date but later than the priority date claimed</li> </ul>		<ul> <li>"T" later document published after the international filing date or priority date and not in conflict with the application but died to understand the principle or theory underlying the invention</li> <li>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</li> <li>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</li> <li>"&amp;" document member of the same patent family</li> </ul>	
	octual completion of the international search October 2004	Date of mailing of the international s	earch report
	ialling address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk	Authorized officer	· · · · · · · · · · · · · · · · · · ·

International application No. PCT/EP 03/14756

## INTERNÄTIONAL SEARCH REPORT

Box I	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This inte	mational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X	Claims Nos.: 7,8,21,22 (partially) because they relate to subject matter not required to be searched by this Authority, namely:
2	Although claims 8,21,22 are directed to a method of treatment of the human/animal body, and claim 7 is directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.  Claims Nos.:  because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3.	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This Inte	mational Searching Authority found multiple inventions in this international application, as follows:
1.	As all required additional search fees were timely paid by the applicant, this international Search Report covers all searchable claims.
2	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the Invention first mentioned in the claims; it is covered by claims Nos.:
Remark	on Protest  The additional search fees were accompanied by the applicant's protest.  No protest accompanied the payment of additional search fees.

information on patent family members

International Application No T/EP 03/14756

Publication Patent document Publication Patent family date member(s) date cited, in search report 749802 B2 04-07-2002 WO 9955855 · A 04-11-1999 ΑU 16-11-1999 ΑU 3402199 A 16-05-2002 747639 B2 ΑU 16-11-1999 3402299 A ΑU 19-12-2000 9909809 A BR 19-12-2000 BR 9909859 A 04-11-1999 CA 2326824 A1 CA 2326825 A1 04-11-1999 WO 9955854 A2 04-11-1999 WO 9955855 A2 04-11-1999 06-06-2001 CN 1298444 T 06-06-2001 1298445 T CN 1073728 A2 07-02-2001 EP 07-02-2001 1073729 A2 EP 08-05-2002 2002512792 T JP 08-05-2002 JP 2002512793 T 12-12-2002 US 2002187954 A1 US 6417169 B1 09-07-2002 US 2003083274 A1 01-05-2003 31-03-2004 WO 02086157 31-10-2002 ΕP 1402060 A2 Α 02086157 A2 31-10-2002 WO 05-08-2004 US 2004152110 A1

international Application No /EP 03/14756

	- BOOLINGIAGO OOMORDED TO DE DE DE DAME			
C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT  Category   Citation of document, with indication, where appropriate, of the relevant passages  Relevant to claim No.				
Category °	Citation of document, with indication, where appropriate, of the relevant passages	restant to diam to		
X	ROCHE JOELLE ET AL: "Semaphorin SEMA3F inhibits cell attachment and spreading in human mammary tumor cells" PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 43, March 2002 (2002-03), pages 22-23, XP001182920 & 93RD ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; SAN FRANCISCO, CALIFORNIA, USA; APRIL 06-10, 2002 ISSN: 0197-016X abstract	1,8,10, 14,15, 21,22		
<b>X</b>	TAKAHASHI TAKUYA ET AL: "Semaphorins A and E act as antagonists of neuropilin-1 and agonists of neuropilin-2 receptors"  NATURE NEUROSCIENCE, vol. 1, no. 6, October 1998 (1998-10), pages 487-493, XP002295428  ISSN: 1097-6256  abstract page 487, left-hand column, lines 16-19 page 492, left-hand column, paragraph 1 figure 1	1,6-8, 10-12		
X	MATTHIES ANNETTE M ET AL: "Neuropilin-1 participates in wound angiogenesis" AMERICAN JOURNAL OF PATHOLOGY, vol. 160, no. 1, January 2002 (2002-01), pages 289-296, XP002295429 ISSN: 0002-9440 page 290, left-hand column, paragraph 2 page 291, left-hand column, paragraph 3 - right-hand column, paragraph 1 page 292, left-hand column figure 3 page 295, left-hand column, last paragraph	1,7-10		
X	HIDEYASU OH ET AL: "Selective induction of neuropilin-1 by vascular endothelial growth factor (VEGF): a mechanism contributing to VEGF-induced angiogenesis" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 99, no. 1, 8 January 2002 (2002-01-08), pages 383-388, XP002255027 ISSN: 0027-8424 page 387, left-hand column, paragraph 2 right-hand column, paragraph 1 figure 3 Discussion ————————————————————————————————————	1,7,8, 10,13		

International Application No
PT/EP 03/14756

	ntion) DOCUMENTS CONSIDERED TO BE RELEVANT	I Delevent to delev No.
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
(	WO 02/086157 A (ALGARTE-GENIN MICHELE; LATIL ALAIN (FR); UROGENE SA (FR); CUSSENOT) 31 October 2002 (2002-10-31)  page 5, lines 18-31 page 11, lines 17-34	1,8, 10-12, 14-16, 21,22
١	page 21, line 1 - page 22, line 26	4 .
	JAY D G: "SELECTIVE DESTRUCTION OF PROTEIN FUNCTION BY CHROMOPHORE-ASSISTED LASER INACTIVATION" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 85, no. 15, August 1988 (1988-08), pages 5454-5458, XP000857275 ISSN: 0027-8424 the whole document	6
		·
		X
		·
	-	
	. *	
	•	

Form PCT/ISA/210 (continuation of second sheet) (January 2004)